Research programme: tropical disease therapeutics - Astellas/DNDi/Unknown Pharmaceutical

Latest Information Update: 06 Apr 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Astellas Pharma; Drugs for Neglected Diseases Initiative Foundation; Unknown
Class Antiparasitics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Chagas disease; Leishmaniasis

Most Recent Events

29 Mar 2018 Astellas, DNDi and seven unknown pharmaceuticals agree to co-develop antiparasitics for Leishmaniasis and Chagas disease
29 Mar 2018 Early research in Chagas' disease in Switzerland, Japan (unspecified route)
29 Mar 2018 Early research in Leishmaniasis in Switzerland, Japan (unspecified route)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.